A generic alternative indicated for Oncology Support. Treatment supports cellular processes that disrupt the growth of specific abnormal cells, promoting better patient outcomes during therapy.
Developed to manage malignant tumor growth by addressing cancer cell replication to alleviate symptoms and support treatment goals in breast and colorectal cancer patients.
Mechanism of Action
Capecitabine is a prodrug that is converted by enzymes in the body into 5-fluorouracil. It targets tumors directly where the conversion is highest, interfering with DNA and RNA synthesis to stop cancer cells from dividing.
Route of Administration
Oral
Onset Time
Variable; weeks for clinical effect
Duration
12 hours
Contraindications
Severe kidney impairment, DPD enzyme deficiency, Hypersensitivity to capecitabine, Pregnancy
Severe Adverse Events
Severe diarrhea, Cardiotoxicity, Liver injury, Severe bone marrow suppression, Severe hand-foot syndrome, Death
Information for Capecitabine is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
